A sample of faint, V magnitude selected, galaxy pairs, having physical separations less than approximately 20h −1 kpc, is used to examine the rise in the merger rate with redshift and the statistical relations between close pairs and the field galaxy population. Redshifts have been obtained for 14 galaxies (V ≤ 22.5) that are in close (θ < 6 ′′ ) pairs, along with a comparison sample of 38 field galaxies. Two color photometry is available for about 1000 galaxies in the same fields. The average redshift of the V ≤ 22.5 field population is 0.36, statistically equal to the average redshift of 0.42 for the pairs. The similarity of the two redshift distributions, ∆z ≤ 0.1, limits any differential luminosity enhancement of close pairs to less than half a magnitude. The pairs are somewhat bluer than the field and have nearly twice the average [O II] detection rate of the field, but the differences are not statistically significant. The field population has an angular correlation at separations of θ ≤6 ′′ higher than the inward extrapolation of ω(θ) ∝ θ −0.8 , which may be a population of "companions" not present at the current epoch, or, luminosity enhancement of intrinsically faint galaxies in pairs. Physical pairs comprise about 7% of the faint galaxies in our survey fields. The same physical separation applied to local galaxies finds only 2.6% in pairs. If the rise in close low relatively velocity pairs with redshift is parameterized as (1 + z) m , then m = 2.9 ± 0.8. If all pairs at low velocities and r ≤ 20h −1 kpc merge, then the average galaxy mass would be 32% smaller at z = 0.4 than locally.

No abstract

No abstract

A 69-year-old woman with a history of goiter and thyrotoxicosis over the previous year was seen for radioiodine therapy. At the time of a previous ablation with I-131, a thyroid scan was performed after administration of Tc-99m sodium pertechnetate. Scintigraphy showed an enlarged thyroid gland with increased thyroid uptake in the neck at its normal location along with mediastinal uptake. Contrast enhanced computed tomography (CT) showed an anterior mediastinal mass. This mass was excised. Histologic study demonstrated an ectopic primary intrathoracic nodular goiter at the site of increased activity seen on Tc-99m pertechnetate imaging.

9530 Background: Bispecific antibodies have shown activity in hematologic (heme) but not solid tumors. ImmTAC molecules are unique TCR–anti-CD3 bispecifics that redirect T cells against intracellular antigens. IMCgp100, an ImmTAC targeted against melanocyte-associated lineage antigen gp100, has shown monotherapy responses in advanced melanoma with associated immune changes. IMCgp100 causes rash and cytokine-mediated AEs, hypothesized to be on-target (gp100) or effector (CD3) mediated. We explored clinical and biological characteristics of pts associated with treatment benefit. Methods: 84 HLA-A2 positive advanced melanoma pts received IMCgp100 on study IMCgp100-01 in 13 dose escalation cohorts. Efficacy was assessed by Kaplan–Meier survival and treatment related AEs (TRAE) reported by CTCAE v4.0. Serum samples evaluated changes in cytokines. A multivariate analysis investigated the relationship between efficacy and safety variables. Results: Demographics: 73% cutaneous (CM), 23% uveal (UM) primaries; 51% LDH > ULN; 25% received prior anti-PD(L)1. 83 (99%) pts had ≥1 TRAE; most commonly in skin (rash 82%, pruritus 69%) or cytokine-mediated (pyrexia 57%); the majority were Grade 1–2 and occurred and resolved within first 3 doses. The 2 most frequent Grade ≥3 TRAEs were rash (26%) and lymphopenia (13%). IMCgp100 induced transient increases in peripheral cytokines (peaking Day 1–2) that attenuated with subsequent doses; cytokine-mediated AE had similar kinetics.1-yr OS was 65% (95% CI: 48–78). In multivariate analysis, longer OS was associated with: LDH ≤ULN (p = 0.002) and any-grade rash occurring within 21 days (p = 0.003); melanoma primary site and prior anti-PD-(L)1 did not significantly affect outcome. In exploratory analyses, longer OS associated with lower baseline serum IL-6 (n = 43) or TNFα (n = 44). Conclusions: IMCgp100 is a first-in-class, TCR-based bispecific with monotherapy efficacy in advanced melanoma. AEs were manageable and consistent with MoA. Association between IMCgp100 efficacy and on-target TRAEs, previously reported for bispecifics to heme lineage antigens, is now recognized for solid tumor lineage antigens. Pivotal studies in UM are ongoing. Clinical trial information: NCT01211262.